


# Opicapone

02/21

**ALTERNATE NAMES:** BIA 9-1067; 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-1,2,4-oxadiazol-5-yl]-3-nitrobenzene-1,2-diol; 2,5-Dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide; (4Z)-4-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-2H-1,2,4-oxadiazol-5-ylidene]-2-hydroxy-6-nitrocyclohexa-2,5-dien-1-one

**CATALOG #:** B3107-1 1 mg  
B3107-5 5 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>15</sub>H<sub>10</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>6</sub>

**MOLECULAR WEIGHT:** 413.2

**CAS NUMBER:** 923287-50-7

**APPEARANCE:** Powder

**PURITY:** ≥ 98%

**SOLUBILITY:** Soluble in DMSO

**DESCRIPTION:** Opicapone is a potent inhibitor of catechol-O-methyltransferase (COMT). It inhibits rat peripheral COMT with ED<sub>50</sub> values below 1.4 mg/kg up to 6 h post-administration. It is approved for use as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease.

**STORAGE TEMPERATURE:** -20 °C

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**REFERENCE:** Bonifácio, M.J., Torrão, L., Loureiro, A.I., et al. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Br. J. Pharmacol. 172(7):1739-52 (2015).

**RELATED PRODUCTS:**

AC-186 (Cat. No. B2980)  
 Entacapone (Cat. No. B1190)  
 S-Adenosyl-L-methionine disulfate tosylate (Cat. No. 2077)  
 Anti-COMT Antibody (Cat. No. A2003)  
 Bromocriptine (mesylate) (Cat. No. 2916)

**DISCLAIMER:** *FOR RESEARCH USE ONLY! Not to be used on humans.*